Pharming Group (NASDAQ:PHAR) Sees Strong Trading Volume – Here’s What Happened

Pharming Group (NASDAQ:PHAR) saw an uptick in trading volume on Wednesday . 6,598 shares were traded during mid-day trading, an increase of 7% from the previous session’s volume of 6,182 shares.The stock last traded at $8.80 and had previously closed at $8.80.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on PHAR shares. Oppenheimer upped their target price on Pharming Group from $30.00 to $39.00 and gave the company an “outperform” rating in a report on Friday, March 14th. Jefferies Financial Group assumed coverage on shares of Pharming Group in a research report on Monday, December 9th. They issued a “buy” rating and a $14.00 target price for the company. Finally, HC Wainwright reissued a “buy” rating and set a $37.00 target price on shares of Pharming Group in a research note on Thursday.

Pharming Group Trading Up 0.1 %

The business has a fifty day moving average price of $8.91 and a 200 day moving average price of $8.61. The company has a market capitalization of $599.29 million, a price-to-earnings ratio of -33.88 and a beta of -0.10. The company has a debt-to-equity ratio of 0.41, a current ratio of 3.53 and a quick ratio of 2.76.

Pharming Group (NASDAQ:PHAR) last released its earnings results on Thursday, March 13th. The company reported $0.05 earnings per share for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.02). Pharming Group had a negative return on equity of 7.65% and a negative net margin of 6.09%. The firm had revenue of $92.70 million for the quarter, compared to analyst estimates of $76.67 million. On average, equities analysts expect that Pharming Group will post -0.2 EPS for the current fiscal year.

Institutional Investors Weigh In On Pharming Group

A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC lifted its holdings in shares of Pharming Group (NASDAQ:PHAR) by 16.8% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 47,997 shares of the company’s stock after purchasing an additional 6,887 shares during the period. Silverberg Bernstein Capital Management LLC owned 0.07% of Pharming Group worth $483,000 at the end of the most recent reporting period. Institutional investors own 0.03% of the company’s stock.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.